Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Cellectis S.A.
  6. Summary
    ALCLS   FR0010425595

CELLECTIS S.A.

(ALCLS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
11/22/2021 11/23/2021 11/24/2021 11/25/2021 11/26/2021 Date
7.685(c) 7.4(c) 7.76(c) 7.84(c) 7.69(c) Last
77 304 128 272 91 909 48 849 96 798 Volume
-2.91% -3.71% +4.86% +1.03% -1.91% Change
More quotes
Estimated financial data (e)
Sales 2021 55,1 M 62,3 M 62,3 M
Net income 2021 -120 M -136 M -136 M
Net cash position 2021 143 M 162 M 162 M
P/E ratio 2021 -2,59x
Yield 2021 -
Sales 2022 65,3 M 73,9 M 73,9 M
Net income 2022 -125 M -141 M -141 M
Net cash position 2022 118 M 134 M 134 M
P/E ratio 2022 -3,75x
Yield 2022 -
Capitalization 350 M 396 M 396 M
EV / Sales 2021 3,75x
EV / Sales 2022 3,55x
Nbr of Employees 277
Free-Float 84,4%
More Financials
Company
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting... 
Sector
Biotechnology & Medical Research
Calendar
12/11 | 05:30pmPresentation
More about the company
Ratings of Cellectis S.A.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about CELLECTIS S.A.
11/24Cellectis S.A. Announces Executive Changes
CI
11/24Cellectis S.A. Announces Resignation of Eric Dutang as Chief Financial Officer, Effecti..
CI
11/24European ADRs Move Lower in Wednesday Trading
MT
11/19Cellectis, Cytovia Therapeutics Expand Gene-Edited Cells Partnership In China
MT
11/18CELLECTIS S A : Cytovia and Cellectis Expand Their TALEN« Gene-Edited iNK Partnership to E..
PU
11/18Cytovia and Cellectis Expand Their TALEN« Gene-Edited iNK Partnershipáto Enable Broader..
AQ
11/18Cytovia and Cellectis Expand TALEN Gene-Edited iNK Partnership?to Enable Broader Collab..
CI
11/12Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Produc..
PU
11/12Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Produc..
GL
11/12Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Produc..
GL
11/12Cellectis Presents First Preclinical Data on UCARTMESO
CI
11/04Cellectis Provides Business Update and Reports Financial Results for Third Quarter and ..
PU
11/04PRELIMINARY NOTE - Form 6-K
PU
11/04Third Quarter 2021 Financial Results
PU
11/04CALYXT : Q3 Earnings Snapshot
AQ
More news
News in other languages on CELLECTIS S.A.
11/24Les ADR européens en baisse mercredi
11/19Cellectis et Cytovia Therapeutics étendent leur partenariat sur les cellules génétiquem..
11/12SOCIETY FOR IMMUNOTHERAPY OF CANCER : Cellectis présente les premières données précliniqu..
11/05EN DIRECT DES MARCHES : Axa, Orange, Euronext, Casino, Airbus, JCDecaux, Spie...
11/05Stop ou encore ?
More news
Analyst Recommendations on CELLECTIS S.A.
More recommendations
Chart CELLECTIS S.A.
Duration : Period :
Cellectis S.A. Technical Analysis Chart | ALCLS | FR0010425595 | MarketScreener
Technical analysis trends CELLECTIS S.A.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 7,69 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
AndrÚ Choulika Chief Executive Officer & Director
Eric Dutang Chief Financial Officer
Jean-Pierre Garnier Non-Executive Chairman
Philippe Duchateau Chief Scientific Officer
Francisco J. Esteva Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
CELLECTIS S.A.-68.48%396
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431